esophageal cancer
Conditions
Interventions
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Malignant neoplasm of thoracic esophagus proved by pathology to be squamous cell carcinoma 2. Clinical staging before treatment is locally advanced (T3-4N0-1M0) or locally early with regional lymph node metastasis (T1-2N1M0); 3. expect survival longer than 6 months; 4. Aged 18~65 years old, KPS score >80 (KPS standard, see Appendix 1); 5. Laboratory test indicators must meet the following requirements: Blood: white blood cells than 4.0x10^9/L, neutrophils or 1.5x10^9/L, platelet count, hemoglobin 90g/L or more than 100x10^9/L; Liver and kidney function: serum bilirubin is lower than the maximum normal value of 1.5 times; ALT and AST are lower than the maximum normal value of 1.5 times; BUN and Cr are within the normal range; 6. Patients who have not received formal anti-tumor therapy; 7. Be able to understand the situation of this study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. the clinical stage before treatment T4, breaking through the esophageal adventitia invasion and surrounding tissue, esophageal perforation high-risk factors have been anti-tumor treatment (including chemotherapy, radiotherapy, surgery); 2. known or suspected of chemotherapy drugs such as paclitaxel, platinum, platinum and other allergies; 3. having or merging with hemorrhagic disease; 4. other non controllable non operable patients; 5. pregnant and lactating patients; 6. psychological, family, social and other factors lead to the absence of informed consent; 7. because of previous surgery, this operation can not be used for gastric reconstruction of the digestive tract; 8. patients with peripheral neuropathy, CTC grade level is more than 2; 9. patients with a history of other malignancies except those with esophageal cancer, except for non melanoma skin cancer and in situ cervical cancer; 10. the researchers considered unsuitable to participate in this study; 11. there are serious heart, lung, liver and kidney dysfunction, hematopoietic diseases, immune system diseases, cachexia and other intolerance surgery patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;OS;side effects; | — |
Countries
China
Contacts
Public ContactLiu Fang
General Hospital of PLA medical
Outcome results
None listed